

# Company Information

## Directors

**Roger H. Kimmel** <sup>1,3,4,5</sup>

*Chairman of the Board*

*Vice Chairman, Rothschild Inc.*

**Paul V. Campanelli**

*President and Chief Executive Officer*

**Shane M. Cooke** <sup>1,4</sup>

*President, Alkermes*

**Nancy J. Hutson, Ph.D.** <sup>3,4,5</sup>

*Retired Senior Vice President, Pfizer Global Research and Development*

**Michael Hyatt** <sup>2,3,4</sup>

*Senior Advisor, Irving Place Capital*

**Douglas S. Ingram** <sup>2,5</sup>

*Former Chief Executive Officer and Director, Chase Pharmaceuticals Corporation*

**William P. Montague** <sup>1,2,3,4</sup>

*Retired Chief Executive Officer and Director, Mark IV Industries, Inc.*

**Todd B. Sisitsky** <sup>3,4</sup>

*Partner, TPG*

**Jill D. Smith** <sup>1,3,5</sup>

*Former Chairman, Chief Executive Officer and President, DigitalGlobe Inc.*

**William F. Spengler** <sup>1,2,5</sup>

*Former President, ChromaDex Corporation*

- 1 Audit Committee Member
- 2 Compensation Committee Member
- 3 Nominating & Governance Committee Member
- 4 Transactions Committee Member
- 5 Operations Committee Member

## Executive Officers\*

**Paul V. Campanelli**

*President and Chief Executive Officer*

**Blaise Coleman**

*Executive Vice President and Chief Financial Officer*

**Terrance J. Coughlin**

*Executive Vice President and Chief Operating Officer*

**Matthew J. Maletta**

*Vice President and Chief Legal Officer*

**Antonio R. Pera**

*President, Par Pharmaceutical*

**Daniel A. Rudio**

*Senior Vice President, Controller and Chief Accounting Officer*

\* Section 16(b) Executive Officers

## Senior Leadership

**Joseph A. Barbarite**

*Executive Vice President, Global Quality and Compliance*

**Patrick Barry**

*Senior Vice President, U.S. Branded Pharmaceuticals*

**Mark Bradley**

*Senior Vice President, Corporate Development*

**Lawrence A. Cunningham**

*Executive Vice President, Human Resources*

**Jennifer E. Dubas**

*Senior Vice President and Chief Compliance Officer*

**Rahul Garella**

*Senior Vice President, Head of International Pharmaceuticals*

**Stephen Mock**

*Senior Vice President, Investor Relations & Corporate Affairs*

**Brandon Rockwell**

*Vice President, Business Development*

**Company Secretary**

**Orla Dunlea**

*International Legal Counsel and Company Secretary*

## Company Information

### Auditors

**PricewaterhouseCoopers LLP**

*Two Commerce Square, Suite 1700*

*2001 Market Street*

*Philadelphia, PA 19103-7045*

### Corporate Counsel

**A&L Goodbody**

*IFSC*

*North Wall Quay*

*Dublin 1*

*Ireland*

**Skadden, Arps, Slate,**

**Meagher & Flom LLP**

*4 Times Square*

*New York, NY 10036*

### Transfer Agent

**Computershare**

*P.O. Box 43001*

*Providence, RI 02940*

*250 Royall Street*

*Canton, MA 02021*

### Investor Relations

**Stephen Mock**

*Senior Vice President, Investor Relations & Corporate Affairs*

+1 845 364 4833

### Annual Shareholder Meeting

**Thursday, June 8, 2017 at 8:00 a.m. Irish Standard Time (IST)**

*First Floor*

*Minerva House*

*Simmons Court Road*

*Ballsbridge*

*Dublin 4*

*Ireland*

### Stock Exchange

Endo common stock is listed on the NASDAQ Global Select Market under the ticker symbol ENDP. Note: NASDAQ quotes are in USD\$.

### SEC Form 10-K

A copy of the company's annual report on Form 10-K, as filed with the U.S. Securities and Exchange Commission (SEC), is available on our website ([www.endo.com](http://www.endo.com)) or may be obtained without charge by writing to:

*First Floor*

*Minerva House*

*Simmons Court Road*

*Ballsbridge*

*Dublin 4*

*Ireland*

### Caution: Forward-looking Statements

This document contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to changes in economic, business, competitive, market and regulatory factors. More information about those factors is contained in Endo's filings with the U.S. Securities and Exchange Commission.

BELBUCA™ is a trademark of BioDelivery Sciences International, Inc. All other trademarks are trademarks of Endo International plc affiliates.

Copyright © 2017 All rights reserved by Endo Pharmaceuticals Inc.